CClinicalTrials.gg
RecruitingNCT07692490ARANMP-LTUpdated Jul 14, 2026

Avoiding Recooling After Normothermic Machine Perfusion in Liver Transplantation

An interventional study of No Recooling Before Liver Implantation and Traditional Recooling Before Liver Implantation in Liver Transplantation (LT), Ischemia-Reperfusion Injury and Early Allograft Dysfunction, sponsored by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies. Recruiting at 14 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The ARANMP-LT study is a multicenter, open-label, randomized, parallel-group, non-inferiority clinical trial designed to evaluate whether avoiding graft recooling after normothermic machine perfusion (NMP) improves early outcomes following liver transplantation. Although graft recooling before implantation is common practice, experimental and preliminary clinical evidence suggests that abrupt temperature changes may contribute to ischemia-reperfusion injury.

Adult recipients of deceased-donor liver grafts preserved with NMP or sequential hypothermic-normothermic machine perfusion (SHNMP) will be randomized in a 1:1 ratio to either standard graft implantation with recooling using cold preservation solution (control group) or implantation without recooling using a room-temperature 5% albumin flush immediately before reperfusion (intervention group).

The primary objective is to compare the incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria, between the two treatment groups. Secondary objectives include evaluation of histopathological ischemia-reperfusion injury using the Suzuki score, vascular and biliary complications, primary non-function, post-reperfusion syndrome, patient and graft survival, length of intensive care unit and hospital stay, perioperative transfusion requirements, and safety outcomes. A total of 170 participants will be enrolled across multiple Italian liver transplant centers and followed for 90 days after transplantation.

02

Conditions studied

  • Liver Transplantation (LT)
  • Ischemia-Reperfusion Injury
  • Early Allograft Dysfunction

Browse trials for

Keywords

  • Liver Transplantation
  • Normothermic Machine Perfusion
  • Ischemia-Reperfusion Injury
  • Early Allograft Dysfunction
  • Organ Preservation
  • Liver Graft
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years.
  • Listed for primary liver transplantation at the participating institution.
  • Assigned a liver graft preserved with normothermic machine perfusion or sequential hypothermic- normothermic machine perfusion (SHNMP).
  • Signed and dated informed consent prior study inclusion.

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients (age \< 18 years)
  • Patients undergoing re-transplantation (history of previous liver transplantation)
  • Patients with acute liver failure
  • Patients undergoing multi-organ transplantation (e.g., liver-kidney, liver-heart)
  • Temporarily unconscious patients
  • Patients unable to freely express consent.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    No Recooling

    No Recooling Before Liver Implantation

    Procedure: No Recooling Before Liver Implantation

  • Active comparator
    Traditional Recooling

    Traditional Recooling Before Liver Implantation

    Procedure: Traditional Recooling Before Liver Implantation

Interventions

  • ProcedureNo Recooling Before Liver Implantation

    After completion of normothermic machine perfusion, the liver graft is flushed with 5% albumin solution at room temperature (20-25°C) and implanted without recooling. The graft remains at near-normothermic temperature throughout the transition from ex vivo perfusion to in situ implantation, avoiding the conventional cold preservation flush before reperfusion.

  • ProcedureTraditional Recooling Before Liver Implantation

    After completion of normothermic machine perfusion, the liver graft undergoes the standard preservation procedure consisting of a cold preservation solution flush before implantation, resulting in graft recooling prior to reperfusion. The remainder of the transplantation procedure follows standard clinical practice.

05

What researchers measure

Primary outcomes

  1. Early Allograft Dysfunction (EAD)

    Incidence of Early Allograft Dysfunction (EAD), defined according to the Olthoff criteria as bilirubin ≥10 mg/dL or INR ≥1.6 on postoperative day 7, or AST/ALT \>2000 IU/L within the first 7 postoperative days.

    Time frame: Within 7 days after liver transplantation

06

Study locations

1 of 14 sites recruiting
  • Università Politecnica delle Marche, AUO delle Marche
    Ancona, 60126, Italy
    Not yet recruiting
  • Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari - Ospedale Giovanni XXIII
    Bari, 70124, Italy
    Not yet recruiting
  • ASST Papa Giovanni XXIII
    Bergamo, 24127, Italy
    Not yet recruiting
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna
    Bologna, 40138, Italy
    Not yet recruiting
  • Ospedale Università Policlinico San Martino - IRCCS
    Genova, 16132, Italy
    Not yet recruiting
  • Università di Modena e Reggio Emilia
    Modena, 41124, Italy
    Not yet recruiting
  • Azienda Ospedale-Università di Padova
    Padova, 35128, Italy
    Not yet recruiting
  • IRCCS ISMETT - Istituto Mediterraneo per i Trapianti e le Terapie ad Alta Specializzazione
    Palermo, 90127, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
    Not yet recruiting
  • Fondazione PTV - Policlinico Tor Vergata
    Roma, 00133, Italy
    Not yet recruiting
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, 00152, Italy
    Not yet recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I - Sapienza Università di Roma
    Roma, 00161, Italy
    Not yet recruiting
  • Fondazione Policlinico "Agostino Gemelli" IRCCS
    Roma, 00168, Italy
    Not yet recruiting
  • Azienda Ospedaliera Universitaria Integrata Verona
    Verona, 37126, Italy
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07692490
Lead sponsor
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jul 7, 2026 (estimated)
Primary completion
Oct 6, 2028 (estimated)
Completion
Oct 6, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Salvatore Gruttadauria
Contact
sgruttadauria@ismett.edu
0912192618 ext. +39 0912192618
Monica Rizzo
Contact
ufficioricerca@ismett.edu
0912192692 ext. +39 0912192692

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion